Delivering High Impact Medicines That Transform Patients' Lives

Martin Mackay, President PharmaTherapeutics

JP Morgan
January 2010
This presentation will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2008 Annual Report on Form 10-K and in our reports on Form 10-Q and Form 8-K.

These reports are available on our website at www.pfizer.com in the "Investors—SEC Filings" section.
Operating Model

Nine Diverse Business Units Supported by Two Research Organizations

BioPharmaceutical Businesses

- Primary Care
- Specialty Care
- Oncology
- Established Products
- Emerging Markets

Diversified Businesses

- Animal Health
- Capsugel
- Consumer Healthcare
- Nutrition

Pharm Sci, Drug Safety, Manufacturing, Finance, etc.
The New R&D Organization

**Footprint**
- R&D biomedical presence in US, Europe, Canada and China
  - 5 Major sites
  - 9 Specialized units
- Reduced site footprint by 35%
- Closed 6 R&D sites/consolidated 4 R&D sites

**Portfolio Prioritization**
- Invest to Win Projects increased 50% to 70%
- Research portfolio prioritization led to a 22% reduction of projects
- Strategic move to biologics and vaccines
Innovative Therapies In Key Areas Of Unmet Medical Need

Neuroscience  Pain/Inflammation  Oncology  Metabolic Disorders

Our Focus Is on High Priority Disease Areas and Enhanced Biologics Capabilities

Vaccines  Infectious Diseases  Biotherapeutics
Early Stage: Human Genetics & Cell Biology Are Revolutionizing Target Selection

Molecular Profiling

Stem Cells

Systems Biology

Target Selection

Human Genetics

Bioimaging
NaV1.7: Exciting New Pain Target

Hypothesis

- NaV 1.7 channel modulator will reduce pain by limiting the frequency of firing of pain sensing nerves

- Sodium channels responsible for detection and conduction of pain
- Human clinical genetic NaV 1.7 mutations have extreme pain phenotypes

CIP

Erythromelalgia

Pharmacological Advances Enabled Us to Lead the Field
Today’s Phase 3 Portfolio

NMEs

- apixaban – VTE Prevention
- Thelin – Pulmonary Hypertension
- Dimebon – Alzheimer’s Disease
- figitumumab – Lung Cancer
- bapineuzumab – Alzheimer’s Disease
- Aprela – Menopausal Vasomotor Symptoms
- apixaban – Renal Cell Cancer
- PF-2341066 - Lung Cancer
- moxidectin – River Blindness
- CP-690,550 – Rheumatoid Arthritis
- Zithromax/chloro – Malaria
- tanezumab – OA Pain
- bosutinib – Chronic Myelogenous Leukemia
- neratinib – Breast Cancer
- Taliglucerase alfa – Gaucher’s Disease
- PF-299804 – Lung Cancer

New Indications

- apixaban – Atrial Fibrillation
- apixaban – Acute Coronary Syndrome
- apixaban – VTE Treatment
- Dimebon – Huntington’s Disease
- Prevnar 13 – Invasive Pneumococcal Disease (adult)
- Macugen – Diabetic Macular Edema

Marketed Products

- Sutent
- Lyrica
- Eraxis
- VFEND
- Celebrex
- Torisel
<table>
<thead>
<tr>
<th>Candidate</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevnar 13 for Adults (Vaccine)</td>
<td>Vaccine</td>
</tr>
<tr>
<td>Tanezumab (NGF Antibody)</td>
<td>Pain</td>
</tr>
<tr>
<td>CP-690550 (JAK3 Inhibitor)</td>
<td>Rheumatoid Arthritis</td>
</tr>
<tr>
<td>Dimebon (MPTP Modulator)</td>
<td>Alzheimer’s Disease</td>
</tr>
<tr>
<td>Bapineuzumab (IV Pass Mono Antibody)</td>
<td>Alzheimer’s Disease</td>
</tr>
<tr>
<td>PF-2341066 (c-Met/ALK Inhibitor)</td>
<td>NSCLC</td>
</tr>
<tr>
<td>Opportunity</td>
<td>Infant</td>
</tr>
<tr>
<td>-------------</td>
<td>--------</td>
</tr>
<tr>
<td>Provide Brodest Coverage Available for the Global Protection of Children Against Pneumococcal Disease</td>
<td></td>
</tr>
<tr>
<td>Status</td>
<td>Approved in 34 countries including the EU and Canada</td>
</tr>
<tr>
<td></td>
<td>U.S. review ongoing</td>
</tr>
<tr>
<td>Est. Peak Sales</td>
<td>&gt; $3 Billion</td>
</tr>
</tbody>
</table>
Pain Therapeutics: Broad Mechanistic Approach, Multiple Modalities

1. **Peripheral Sensitization**
   - Celebrex (gout, Ph3b)
   - Tanezumab (Ph3)
   - CGRP antibody (migraine, Ph1)
   - Peripheral u opioid agonist (LD)

2. **Pain Transduction & Conduction**
   - Nav1.7 blocker (LD)
   - Nav1.8 blocker (Ph1, SDS)
   - TrpV1 blocker (ESD)
   - TrkA blocker (SDS)
   - TRESK opener (ESD)

3. **Pain Transmission & Processing**
   - GABA_A agonist (SDS)

4. **Pain Perception/Central Sensitisation**
   - Lyrica (Post op pain, Ph3b)
   - FAAH inhibitor (Ph2)
   - Delta opioid agonist (Ph2)
   - MAGL inhibitor (SDS)
Tanezumab: Pain Responder Rates
Osteoarthritis

Percent of Patients

30% Responders
Much improved/
Moderate improvement

50% Responders
Very much improved/
Substantial improvement

Active treatment group vs. placebo: * p ≤ 0.01; *** p ≤ 0.0001
CP-690,550:
RA Phase 2 Program Conclusions

- 4/4 studies achieved statistical significance on the primary endpoint (ACR20 Response)
- Extensive Phase 2 RA Program enrolled >1,000 patients and explored a CP-690,550 dose range of 1 to 30 mg BID
- CP-690,550 dosed ≥ 3 mg BID was generally efficacious, compared to placebo, as measured by:
  - ACR response rates
  - Changes from Baseline in the DAS and DAS remission rates
  - Improvements in patient reported outcome measures including HAQ DI
- Efficacy was seen early (within 2 weeks) when CP-690,550 was dosed either as monotherapy or on background MTX
- Doses of 5 and 10 mg BID have been advanced into Phase 3

![CP-690,550: Study 1035 - Week 12 ACR Response Rate (nonresponder imputation)](image)
Multiple Approaches To Treat AD Spanning Small Molecules, Biologics, And Vaccines

Amyloid Pathway
1. Anti-Aβ antibody (Ph 3, Ph 2, PC)
2. Anti-Aβ vaccine (Ph 2)
3. RAGE antagonist (Ph 2)
4. γ-Secretase inhibitor (Ph 1, LD)
5. BACE inhibitor (LD)

Tau Pathway
6. Tau vaccine (LD)

Modulators of Neurotransmission
7. 5HT4 partial agonist (PC, LD)
8. H3 antagonist (Ph 1)
9. 5-HT6 antagonist (Ph 1)
10. PDE9 inhibitor (Ph 2)

Neuroprotection / Modulator of Neurotransmission
11. Dimebon (Ph 3)
Dimebon: Affects Cognition In Mild-To-Moderate AD

Treatment Effect

<table>
<thead>
<tr>
<th></th>
<th>2.0</th>
<th>4.0</th>
<th>5.9</th>
<th>6.9</th>
</tr>
</thead>
<tbody>
<tr>
<td>p</td>
<td>0.0077</td>
<td>&lt; 0.0001</td>
<td>&lt; 0.0001</td>
<td>&lt; 0.0001</td>
</tr>
</tbody>
</table>

Mean Change From Baseline Score ADS-cog

Clinical Improvement

Clinical Deterioration

* Similar results were seen with the MMSE over 1 year
Four Studies in Over 4,000 Patients Worldwide
 Patients Are Stratified by ApoE4 Carriers vs. Non-Carriers
 Co-Primary Efficacy Endpoints – Validated Cognitive and Functional Scales
 Phase 2 Data Presented at ICAD – July 2008
  - Safety and Efficacy Findings Support Decision of Ongoing Global Phase 3 Program
  - Pre-Specified Efficacy Analysis Did Not Reach Significance in the Total Population
  - Encouraging Trends Were Observed in Post Hoc Analyses
    - Trends Were Observed in the Cognitive Endpoints ADAS-cog and NTB in the Total Population
    - Statistically Significant and Clinically Meaningful Effects Were Observed in Multiple Endpoints in ApoE4 Non-Carriers
    - In ApoE4 Carriers, Favorable Directional Changes Were Seen in Some Endpoints, Warranting Further Study
Novel c-Met/ALK Inhibitor is the First Agent in Clinical Development to Selectively Target Sub-group of NSCLC Patients

ASCO 2009 – Presented new study results from an expansion cohort of a Phase 1 study in patients with NSCLC carrying the ALK (anaplastic lymphoma kinases) fusion gene

Among 19 NSCLC patients who had an EML4-ALK mutation treated with PF-2341066, 10 have had a partial response, with three unconfirmed; the duration of response has ranged from 2+ to 23+ weeks. Additionally, five patients have had stable disease, with the duration of response ranging from 8+ to 40 weeks.
PF-2341066 (cMet Alk)

43 yr old Male with Stage IV NSCLC positive for EML4-ALK

Pre-Treatment (FLT-PET)

After 1 Cycle PF-2341066
### Areas of Interest

<table>
<thead>
<tr>
<th>Area</th>
<th>Types of Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer’s Disease</td>
<td>Licensing</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Co-develop/Co-promote</td>
</tr>
<tr>
<td>Inflammation &amp; Immunology</td>
<td>Alliances</td>
</tr>
<tr>
<td>Oncology</td>
<td>Venture Investments</td>
</tr>
<tr>
<td>Pain</td>
<td>M&amp;A</td>
</tr>
<tr>
<td>Psychosis</td>
<td>Out Licensing</td>
</tr>
<tr>
<td></td>
<td>Academic</td>
</tr>
</tbody>
</table>

- Biotherapeutics
- Vaccines
- Biomarkers
- Regenerative Medicine
- Consumer Healthcare
- Nutritionals
- Established Products
- Emerging Markets